In dasatinib-treated CML patients, the expanded (TCR-Vβ+) and residual (TCR-Vβ−) CD8+ T-cell populations were phenotypically similar and resembled healthy memory CD8+ T-cells. The gene discussed is CD8A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.